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Abstract
Background: Various treatments of giant cell tumor of bone (GCTB) included in curettages and resections and with
adjuvant are exerted, but the best treatment is controversial. The aim of the study was the identification of
individual risk factors after various treatments in GCTB.
Methods: A total of 179 patients treated for GCTB between 1998 and 2010 were concluded in the retrospective
study. All patients were treated with intralesional curettage, extensive curettage, or wide resection. Mean follow-up
was 60.2 ± 18.7 months (36~112 months). Age, gender, tumor location, Campanacci grade, soft tissue extension,
pathological features, and surgical methods were performed to univariate Kaplan-Meier survival analysis and
multivariate Cox regression analysis.
Results: The local recurrence rates of intralesional curettage (41.9 %) and extensive curettage (19.0 %) were
significantly higher than that of wide resection (7.7 %). The higher risk of local recurrence was found for soft tissue
extension (hazard = 7.921, 95 % CI 1.107~56.671), compared with no statistical significances between gender,
location, Campanacci grade, pathologic fracture, and local recurrences, which were shown by Kaplan-Meier analysis.
However, recurrence-free survival (RFS) of patients younger than 30 was significantly lower than that of patients
older than 30. The RFS of pathologic fracture patients with soft tissue extension was significantly lower than that of
pathologic fracture patients without soft tissue extension. Multivariate Cox regression analysis indicated that the
independent variable that contributed to recurrence-free survival was soft tissue extension and surgical methods.
The RFS of extensive curettage had no statistically significant difference with wide resection and was significantly
higher than that of intralesional curettage. Use of high-speed burring and bone cement significantly decreased the
local recurrence rate.
Conclusions: Age (below 30 years), gender, tumor location, Campanacci grade, and pathologic fracture have no
statistically significant influence on local recurrences. Soft tissue extension and intralesional curettage of surgical
methods increased the RFS. The results of the present study suggested that compared with curettage and wide
section, treatment of GCTB by extensive curettage could provide the favorable local control and functional
recovery.
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Background
Giant cell tumor of bone (GCTB), or osteoclastoma, is a
neoplasm with potential malignancy, accounting for ap-
proximately 5 % of all primary bone tumors and typically
occurring in the epiphyses of long bones [1, 2]. Gener-
ally, GCTB consists of three cell types, mononuclear his-
tiocytic cells, multinucleated giant cells, and neoplastic
stromal cells [3], and has been classified into three
grades by its histological appearances [4]. However, the
clinical and prognostic value of the tumor’s grading has
been disputed [5–8].
Although histopathological characteristics of most
GCTB are benign, some types still have a high rate of
local recurrence and the ability to metastasize with a re-
currence rate of 2.5–45 % [9–12]. Those cases have post-
operative recurrence within 24 months after the surgery
[13, 14]. However, many studies used to show that X-ray
grading, pathological fracture, and histological grading
have no impact on tumor recurrence, invasiveness, and
distant metastasis, which leads to the overlook and
underestimation of the recurrence in practice. But with
surgical methods being taken into consideration, more
and more studies reveal that the recurrence rate of
GCTB varies significantly with the factor [15–17] and
debates on determining the best one retain for a long
period.
It is reported that recurrence rates of GCTB would
range from 0 to 65 %, depending on the type of treat-
ment and local presentation of the tumor [17–19]. Gen-
erally, GCTB is always treated with intralesional
curettage and wide resection. The former one has a low
risk of invasiveness and can preserve the joint adjacent
to the tumor [20], the recurrence rate of which is from 1
to 65 % [15–18, 21]. Other studies also report lower re-
currence rate with the use of polymethylmethacrylate in
intralesional curettage; however, the recurrence rate is
similar to the result in the study of Blackley et al. and
Turcotte et al. without using any adjuvant [16–20]. Wide
resection is another recommended surgical therapy
when the bone is extensively destructed or possibility to
save the adjacent joint is small [22]. Lots of studies have
suggested that wide resection contributes to the decrease
in the risk of local recurrence as compared with intrale-
sional curettage; moreover, wide resection may increase
the recurrence-free survival rate to 84 to 100 % [17–19].
However, the wide resection is associated with higher
rates of surgical complications and accompanied by con-
siderable functional impairment.
In the present research, we retrospectively reviewed
179 GCTB patients treated with intralesional curettage,
extensive curettage, and wide resection between 1998
and 2010. Recurrence rate was first determined accord-
ing to different surgical methods. Log-rank test of
Kaplan-Meier survival analysis was performed for
clinicopathologic features and surgical methods. Multi-
variate Cox regression was used to analyze the risk factors




We retrospectively identified 179 patients diagnosed as
GCTB from 1998 to 2010 at the Third Affiliated
Hospital of Kunming Medical University, including 99
male patients and 80 female patients. The average age of
the patients was 32.0 ± 9.5 (13–64). The average follow-
up time was 60.2 ± 18.7 months (36–112). The visiting
intervals were 3 months for the first 2 years after surger-
ies, 6 months for the third to fifth years, and 12 months
for patients after surviving the fifth year. Routine follow-
ups included physical examination, X-ray examination,
and chest computerized tomography (CT). The patients
were not recalled specifically for the study; all the data
were retrieved from medical records.
Inclusion and exclusion criteria
Inclusion criteria covered the following: (1) Benign
GCTB was confirmed by histopathological diagnosis ac-
cording to the 2002 World Health Organization classifi-
cation of GCTB [23]; (2) Patients had explicit imaging
data including X-ray, CT, or magnetic resonance for
diagnosis; (3) Patients had the complete records includ-
ing diagnosis, therapy, follow-up, and recurrence. Exclu-
sion criteria covered the following: (1) malignant GCTB;
(2) the follow-up was shorter than 36 months.
Classification of GCTBs
Levels of GCTBs were graded as grades I, II, and III ac-
cording to the Campanacci method [15]. In our study,
25 patients were identified as grade I, 78 patients were
identified as grade II, and 76 patients were identified as
grade III.
Surgery methods of GCTB patients
Patients enrolled in the present study were treated with
intralesional curettage, extensive curettage, and wide re-
section. Intralesional curettages were performed as a
wide cortical window was created to observe the tumor
cavity and the tumor tissue was removed with a curette;
for extensive curettage, chemical inactivation was per-
formed on the basis of curettage and tumor cavity was
packed carefully with autologous, allogenic bone grafts
or polymethylmethacrylate (PMMA). According to
Campanacci grade, soft tissue extension, and tumor
location, the surgical methods of patients were deter-
mined. Forty-three patients were treated with curettage,
84 patients were treated with extensive curettage, and 52
patients were treated with wide resection.
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Data collection
Data were collected from the medical records and in-
cluded in information on age, gender, tumor location,
Campanacci grade, soft tissue extension, pathological
fracture, and surgical methods (Table 3).
Ethics
The project was approved by the Third Affiliated
Hospital of Kunming Medical University. The ethics
committee approved the relating screening, inspection,
and data collection of the patients, and all subjects
signed a written informed consent form. All works were
undertaken following the provisions of the Declaration
of Helsinki.
Statistical analysis
Differences in the recurrence-free survival between dif-
ferent surgical methods or clinicopathologic features
were calculated with log-rank test of Kaplan-Meier sur-
vival analysis. Multivariate Cox regression was used to
analyze the risk factors of local tumor recurrence. Test
of factor interactions was performed to identify potential
confounding variables. Statistical analysis was performed
using SPSS version 20.0 (IBM, Armonk, NY, USA).
Results
Local recurrence of patients treated with different
surgical methods
Thirty-eight of 179 patients (21.2 %) had local recur-
rence of GCTB and the mean time to local recurrence
was 16.9 ± 9.0 months (5–46 months) (as shown in
Table 1). Six cases of recurrence patients were found
with pulmonary metastasis (3.4%), 4 cases had local re-
currence and pulmonary metastasis while 2 cases had
pulmonary metastasis alone. As shown in Table 1, the
patients treated with intralesional curettage had the
highest recurrence rate, with 18 of 43 patients (41.9 %)
found with local recurrence, while the recurrence rates
of patients treated with extensive curettage and wide re-
section were only 19.0 and 7.7 %, respectively.
RFS analysis in patients by Kaplan-Meier
There was no significant difference in RFS between dif-
ferent genders, tumor locations, Campanacci grades, or
pathological fracture conditions (Fig. 1a–c, f ). However,
the RFS of patients below 30 years was significantly
lower than that of patients older than 30 years (Fig. 1d).
And the RFS of patients with soft tissue extension was
significantly lower than that of patients without (Fig. 1e).
Regarding surgical methods, a different therapy had dra-
matic difference impact on the RFS (Table 2; Additional
file 1: Table S2; Fig. 2) and the pattern was similar to
that of the recurrence rate.
Multivariate analysis by Cox regression
Our results showed that the gender, age, location, Cam-
panacci grade, and pathological fracture had no influ-
ence on the recurrence rate. But soft tissue extension
would increase the risk of having local recurrence
(Table 3). Moreover, wide resection could significantly
reduce the local recurrence risk in GCTB patients. And
the patients treated with extensive curettage also got
lower recurrence risk compared with those treated with
curettage (Table 3).
Discussion
GCTB is a severe type of tumor with a high recurrence
rate, strong invasiveness, and complicated biological
characteristic. Generally, it is quite difficult to predict
the prognosis of the GCTB patients just with the
methods of radiology, histology, or other clinical factors.
In the present study, the gender ratio was 1.24, includ-
ing 99 male patients and 80 female patients, which was
similar to the research of Niu [24]. This value varies sig-
nificantly in different countries, from 0.8 in USA to 0.5
in Sweden [2]. However, we have found that gender was
not a key factor influencing the recurrence-free survival
rate of GCTB (Fig. 1a), while patients younger than 30
had a much lower recurrence-free survival rate than pa-
tients older than 30, which was indicative of the influ-
ence of age on the recurrence rate. This may be a result
of the high level of bone metabolism of younger patients
[25, 26]. But the result of Cox regression was opposite to
Kaplan-Meier survival analysis and inferred that age was
not an independent factor influencing the recurrence.
When combined with other factors, it made no impact
the recurrence rate of the patients factors (Table 3). The
result of univariate Kaplan-Meier analysis was uncor-
rected on the account of possible confounding variates.
To access the association of each variate with
recurrence-free survival while controlling for the effects
of other variates, multivariate Cox regression was
Table 1 Local recurrence rate treated with different surgical
methods
Treatment Total number Recurrence Recurrence
rate (%)
Wide resection 52 4 7.7
Extension curettage 84 16 19.0
Abrasion + bone grafting 35 8 22.9
Abrasion + PMMA 49 8 16.3
Curettage 43 18 41.9
Alcohol 16 6 37.5
Iodine tincture or H2O2 27 12 44.4
Total 179 38 21.2
H2O2 hydrogen peroxide, PMMA polymethylmethacrylate
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performed. In our study, we found that age was not an
independent factor of recurrence after Cox regression
correction. Previous studies have also reported that re-
currence rate is higher among patients with GCTB at
distal radius [2, 18], whereas, according to our data,
there was no significant difference among patients with
different focus locations (Table 3). Moreover, another






Fig. 1 Results of Kaplan-Meier analysis and the log-rank test. a comparison between genders; b comparison among different locations; c comparison
among different Campanacci grades; d comparison among different ages; e comparison between patients with soft tissue extension and
patients without; f comparison between patients with pathological fracture and patients without
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Campanacci grade [27], was also found to have no differ-
ence on the recurrence rate of GCTB in our study
(Table 3). We thought this might result from the ten-
dency of applying wide resection to high Campanacci
grade patients in our study; 57.9 % of patients with grade
III and 9 % of patients with grade II were treated with
wide resection (Additional file 1: Table S1). We also re-
ported that the pathological fracture conditions of pa-
tients had no influence on the recurrence rate
(Additional file 1: Table S2). The only clinicopathologic
factor contributing to the recurrence rate change was
soft tissue extension. There were 25 patients with soft
tissue extension in the present study, and the result of
multivariate Cox regression is 7.021 (p = 0.039),
indicating the increase of recurrence rate of GCTB due
to soft tissue extension. It can be explained that per-
forming the complete removal of tumor tissue is tech-
nically difficult and the current lack of applicable local
adjuvants after surgery, which eventually leads to the
high recurrence rate in GCTB patients with soft tissue
extension [28, 29]; some alternative methods are impera-
tive to solve this issue [30, 31].
Results of multivariate Cox regression showed that
the surgical method was an independent factor influ-
encing the recurrence rate. Among the three types of
surgical methods, wide resection had the lowest recur-
rence rate (7.7 %) and the recurrence-free survival rate
after 60 months was 92.3 %. However, restricted by
some side effects, wide resection should not be taken
as a standard method for GCTB treatment [32]. For
curettage method, it has been concluded to have a
high recurrence rate [14, 33], but our results were in-
consistent with the previous studies. Patients treated
with iodine tincture or hydrogen peroxide after the
surgery had a recurrence rate of 44 %, and patients
treated with alcohol had an even better prognosis
(recurrence rate of 37.5 %). The difference in the re-
currence rates between different adjuvants was not
significant (Table 3). For the patients treated with ex-
tensive curettage, the two adjuvants, bone grafting and
polymethylmethacrylate, both significantly reduce the
recurrence rate compared with the curettage method.
Table 2 Recurrence-free estimates at 60 months based on
different surgical methods
Treatment Recurrence-free survival rate SE
Wide resection 0.923 0.037
Extension curettage 0.810 0.043
Abrasion + bone grafting 0.771 0.071
Abrasion + PMMA 0.837 0.053
Curettage 0.581 0.075
Alcohol 0.625 0.121
Iodine tincture or H2O2 0.556 0.096
Total 0.788 0.031

























Fig. 2 Kaplan-Meier analysis and the log-rank test among the influence of different surgical methods
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Previous studies attribute the good performance of ex-
tensive curettage to the application of abrasion and
polymethylmethacrylate. In our study, the local recur-
rence rate of wide resection was significantly lower
than that of intralesional curettage and extensive cur-
ettage (Table 1), and the recurrence-free survival rate
of intralesional curettage was significantly lower than
that of wide resection and extensive curettage
(Additional file 1: Table S2). It indicated that wide
resection and extensive curettage treatment were
more applicable to patients than intralesional curet-
tage based on lower recurrence rate and higher
recurrence-free survival rate. However, wide resection
treatment frequently causes serious complications in-
cluding functional impairment of the extremities.
There was no significance of recurrence-free survival
rate between wide resection and extensive curettage
(Additional file 1: Table S2). Taken together, extensive
curettage should be a feasible and effective treatment
for GCTB patients.
There were limitations in this study. Firstly, there was
a lack of the detailed information of patients recalled or
phone interviewed on account of the nature of retro-
spective data analysis. Secondly, the retrospective study
was single center. Thus, the finding should be validated
with a prospective, multi-center and larger size sample
study, which aims to obtain the feasible and effective
treatment for GCTB patients.
Conclusions
In summary, age, gender, tumor location, Campanacci
grade, and pathologic fracture had no statistically signifi-
cant influence on local recurrences of GCTB. Soft tissue
extension and intralesional curettage of surgical methods
were independent risk factors of local recurrence of
GCTB. The results of the present study suggested that
compared with curettage and wide section, treatment of
GCTB by extensive curettage could provide the favor-
able local control and functional recovery. Our study
might provide potential guiding significance for the eli-
gible treatment of GCTB in the future.
Additional file
Additional file 1: Tables S1 and S2. Table S1. Patient demographics.
Table S2. Pairwise comparisons for the recurrence-free survival rate of
different surgical methods. (DOC 65 kb)
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Table 3 Hazard of recurrence in association with multiple
factors
Parameter Hazard 95 % CI P value
Gender
Male 0.921 0.469–1.807 0.810
Female 1.000
Age
≤30 1.595 0.800–3.178 0.185
>30 1.000
Location
Distal femur 2.242 0.630–7.791 0.212
Proximal tibia 0.659 0.129–3.361 0.616
Distal radius 2.049 0.284–14.766 0.477
Proximal femur 2.090 0.332–13.157 0.432
Proximal humerus 2.186 0.356–13.420 0.398
Distal tibia 2.736 0.593–12.867 0.195
Proximal fibula 3.325 0.501–22.073 0.213
Sacrum 0.411 0.058–2.903 0.373
Others 1.000 2.2
Campanacci grade
I 2.199 0.234–20.672 0.491
II 3.000 0.405–22.196 0.282
III 1.000
Soft tissue extension
With extension 7.921 1.107–56.671 0.039
Without extension 1.000
Pathological fracture
With fracture 1.336 0.507–3.517 0.558
Without fracture 1.000
Treatments
Wide resection 0.044 0.011–0.175 0.000
Extension curettage
Abrasion + bone grafting 0.144 0.044–0.471 0.001
Abrasion + PMMA 0.113 0.034–0.375 0.000
Curettage
Alcohol 0.410 0.100–1.682 0.216
Iodine tincture or H2O2 1.000
PMMA polymethylmethacrylate, H2O2 hydrogen peroxide, CI
confidence interval
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